about
Quality indicators in headache care: an implementation study in six Italian specialist-care centres.Paracetamol: new vistas of an old drug.Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial.Basal cutaneous pain threshold in headache patients.Validation of potential candidate biomarkers of drug-induced nephrotoxicity and allodynia in medication-overuse headacheComparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study.Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments.Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment.Impact of continuing or quitting smoking on episodic cluster headache: a pilot surveyA genome-wide analysis in cluster headache points to neprilysin and PACAP receptor gene variantsSerum protein changes in a rat model of chronic pain show a correlation between animal and humansSpotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.Proteomic research of proteins involved in pain expression in an animal model of chronic pain.Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy.A Critical Evaluation on MOH Current Treatments.Response to: "Drugs for treatment for alcohol use disorders expose to interactions with others … for little benefit if any"Rare primary headaches in Italian tertiary Headache Centres: Three year nationwide retrospective data from the RegistRare NetworkDrug-drug interactions in the treatment for alcohol use disorders: A comprehensive reviewPharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study
P50
Q33644239-7006910C-942C-4269-A33C-75C660E1B430Q34001974-C391AB2A-D1E9-48C2-8A26-78765A0E1793Q34306281-7D5251B9-779E-4C83-B52C-B134161D8C8EQ34981852-D801DA7D-D981-4E18-BF46-8C44249C4756Q35952546-A060E3BB-F21A-464A-AE94-91FF70F1C83FQ36357113-5B7D79A8-73C2-4436-8E44-DCF7FE67B2F6Q36662893-B7D638B7-3646-4183-8878-43B8BD34E295Q36869674-F8DD098F-BA63-428D-9A8C-3C72AC98124EQ36922717-39D47AC6-8D63-4C6E-87E6-918D443A8881Q37496761-A9E89F39-D392-4BED-9367-E3B3A5EAF36AQ37618042-5AE92915-0633-44A2-B904-E9D7020E39DFQ39242677-40F45772-CF52-474E-A187-F8C74DE86B10Q39449789-329B7A1C-3B75-4463-AE85-34FFEB7B2D03Q43085587-29643663-4B60-465E-8EAD-43D6C5B9C855Q47133621-8234790A-C612-421E-B60C-0C4B163080B9Q54795534-B5395EBD-F83E-470E-94DE-64C9B6E6BF9BQ56357437-CA4A1AA2-8351-47C1-8FA4-7A203D8D3E89Q56374566-6EF0A190-A51C-4869-8890-79B6EABA95EDQ56377195-F75CC02E-14C1-4CA5-B8B0-F1F793A40E5BQ57176921-72F939AC-8AE6-4703-AB33-D97B1BA7CC77
P50
description
researcher ORCID ID = 0000-0001-9589-2782
@en
wetenschapper
@nl
name
Simona Guerzoni
@ast
Simona Guerzoni
@en
Simona Guerzoni
@es
Simona Guerzoni
@nl
type
label
Simona Guerzoni
@ast
Simona Guerzoni
@en
Simona Guerzoni
@es
Simona Guerzoni
@nl
prefLabel
Simona Guerzoni
@ast
Simona Guerzoni
@en
Simona Guerzoni
@es
Simona Guerzoni
@nl
P1153
15519299500
P21
P31
P496
0000-0001-9589-2782